论文部分内容阅读
目的:评价阿德福韦酯与胸腺肽α_1联用对伴有HBV感染肝细胞癌患者术后的疗效。方法:选取2014年1月—2015年12月间收治的伴有HBV感染肝细胞癌患者80例,将其分为A组43例和B组37例;两组患者均接受肝细胞癌(HCC)切除手术治疗,B组患者在对照组基础上再加用阿德福韦酯与胸腺肽α_1联用治疗,比较两组患者治疗后的肝功能各指标值的变化情况。结果:两组患者手术治疗前白蛋白、总胆红素、ALT和AST等各指标无统计学意义(P>0.05);B组患者术后6月和术后1年各项肝功能指标均明显优于A组(P<0.05)。结论:伴有HBV感染肝细胞癌患者在HCC手术的基础上,给予阿德福韦酯与胸腺肽α_1联用治疗,有助于其肝功能指标的改善,巩固手术治疗效果。
Objective: To evaluate the efficacy of adefovir dipivoxil combined with thymosin α_1 in the treatment of hepatocellular carcinoma patients with HBV infection. Methods: Eighty patients with HBV-infected hepatocellular carcinoma (HCC) who were admitted between January 2014 and December 2015 were selected and divided into group A (43 cases) and group B (37 cases). Both groups received hepatocellular carcinoma (HCC ) Resection surgery, B group patients in the control group plus adefovir dipivoxil and thymosin α_1 combination therapy, the two groups of patients after treatment of liver function index values changes. Results: The indexes of albumin, total bilirubin, ALT and AST in two groups before operation were not statistically significant (P> 0.05). The indexes of liver function in group B were 6 months after operation and 1 year after operation Obviously superior to group A (P <0.05). Conclusion: Patients with hepatocellular carcinoma accompanied by HBV infection treated with adefovir dipivoxil and thymosin alpha 1 on the basis of HCC surgery may be helpful to improve their liver function and consolidate the effect of surgery.